Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

Eli Lilly-backed Zephyr AI secures $111m for precision medicine tech

Mar 15, 2024 - pharmaceutical-technology.com
Zephyr AI, a US-based healthcare technology company, has secured $111m in a Series A funding round to further develop its AI platform aimed at improving patient care and research. The platform curates large datasets and uses AI algorithms to create tools and products for the healthcare industry, with a current focus on oncology and cardiometabolic diseases. The funds will be used to increase the company's workforce and enhance its datasets.

The company, founded in 2021 by investment firm Red Cell Partners, aims to democratize precision medicine by using AI to extract insights for better patient stratification and response predictions. The recent funding will also support the expansion of Zephyr AI's scientific and commercial teams and the advancement of its training and validation datasets. The AI market is projected to be worth $908.7bn by 2030, according to GlobalData.

Key takeaways:

  • Zephyr AI has raised $111m in a Series A financing round to advance its AI platform that aids in improving patient care and research.
  • The company's work focuses on curating large datasets and using AI algorithms to build tools for the healthcare industry, with a current focus on oncology and cardiometabolic diseases.
  • Zephyr AI plans to use the funds to expand its scientific and commercial teams and advance its training and validation datasets.
  • Eli Lilly, a backer of Zephyr AI, has previously invested in the AI space, partnering with Genesis Therapeutics and Isomorphic Labs for drug development using AI.
View Full Article

Comments (0)

Be the first to comment!